Oral targeted therapies

被引：0

作者：

Etienne-Selloum, Nelly ^{[1
,2
]}

机构：

[1] Univ Strasbourg, Lab Bioimagerie & Pathol LBP Equipe Tumoral Signa, Fac Pharm, Unistra,CNRS,UMR 7021, 74 Route Rhin,CS 60024, F-67401 Illkirch Graffenstaden, France

[2] Ctr Lutte Canc Paul Strauss, Dept Pharm, 3 Rue Porte Hop, F-67000 Strasbourg, France

来源：

ACTUALITES PHARMACEUTIQUES | 2018年 / 57卷 / 578期

关键词：

angiogenesis; BCR/ABL; BRAF; EGFR; kinase inhibitor; MEK; targeted therapy;

D O I：

10.1016/j.actpha.2018.05.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Lack of selectivity associated with a low therapeutic index of cytotoxic drugs together with improved knowledge of the carcinogenesis mechanisms have led to the development of a new therapeutic strategy for cancer which is more targeted and theoretically less toxic. Anticancer targeted therapies can kill cancer cells more selectively by interfering with specific protein or process involved in cancer growth. These treatments have considerably improved survival and quality of life of patients, most of them being self-administered at home. (C) 2018 Elsevier Masson SAS. All rights reserved

引用

页码：13 / 18

页数：6